SIETES :: 93212 citas

Resultados de la búsqueda por JANSSEN REFINAR BÚSQUEDA

1.

Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2021;384:18 de febrero. [Ref.ID 103836]

2.

Dal-Ré R, Caplan AL, Gluud C, Porcher R. Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. Ann Intern Med 2020:20 de noviembre. [Ref.ID 103783]

3.

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020;396:13 de octubre. [Ref.ID 103744]

4.

Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]

5.

Beddoes ZM. Johnson & Johnson, Purdue and other opioid-peddlers face a reckoning. The Economist 2019:1. [Ref.ID 103165]

6.

Pinto T. Los nuevos anticoagulantes obligan a las farmacéuticas a pagar cientos de millones para evitar juicios . eldiario.es 2019:31 de marzo. [Ref.ID 103065]

7.

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

8.

Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]

9.

Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]

10.

Anónimo. EMA committee recommends approval of ustekinumab for Crohn’s. DIA Daily 2016:2. [Ref.ID 100685]

11.

Anónimo. Cancer drug companies slashing prices following closure of NHS’ Cancer Drugs Fund. DIA Daily 2016:1. [Ref.ID 100585]

12.

Anónimo. ‘Sí’ de la UE a un antipsicótico de Janssen de acción larga. Correo Farmacéutico 2016:17. [Ref.ID 100408]

13.

Cohen D. Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device. BMJ 2015;351:h6431. [Ref.ID 99730]

14.

Anónimo. Simeprevir. Olysio. Hepatitis C. PAM 2014;38:734-40. [Ref.ID 98081]

15.

Anónimo. China multa a Glaxo con 379 millones por sobornos en hospitales. El País 2014:22 de septiembre. [Ref.ID 98018]

16.

17.

Diamant M, Morshink LM. SGLT2 inhibitors for diabetes: turning symptoms into therapy. Lancet 2013;382:917-8. [Ref.ID 96103]

18.

Lawitz E, Ghalib R, Rodríguez-Torres M, Younossi Z, Corregidor A, Jacobson I, Callewaert K, Symonds W, Picchio G. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. In: Advances in ARV and Anti-Hepatitis C Virus Therapy. 20th Conference on retroviruses and opportunistic infections. Atlanta 2013:3-6 marzo. [Ref.ID 95201]

19.

Sax P. Simeprevir and sofosbuvir submitted to FDA - Clock ticking on boceprevir, telaprevir, even interferon. Journal Watch 2013:11 de abril. [Ref.ID 95200]

20.

Anónimo. FDA staff questions safety of novel diabetes drug. DIA Daily 2013:9 de enero. [Ref.ID 94622]